9to5google

Here are all of the fun like button animations in YouTube’s redesign

Like Pokémon, it’s fun to try and snatch up every new custom like button in YouTube’s redesign. One user put together an animated list of every new icon. Part of YouTube’s broader new design on ...
Nasdaq

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
Business Insider

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...
Cure Today

What to Know About Early-Stage Urothelial Carcinoma

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...
The New York Times

Medicare Will Require Prior Approval for Certain Procedures

A pilot program in six states will use a tactic employed by private insurers that has been heavily criticized for delaying and denying medical care. By Reed Abelson and Teddy Rosenbluth Like millions ...
Seeking Alpha

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...
KTLA

Deion Sanders’ cancer battle, and the telltale symptom you shouldn’t ignore

News that NFL legend Deion Sanders is recovering after a battle with bladder cancer has sparked an important conversation about a form of cancer that is often under-discussed and underfunded in ...
Morningstar

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder ...

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
MedPage Today

New Treatment Options for Non-Muscle-Invasive Bladder Cancer

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...
Medscape

FDA Bucks Advisors to Approve Mitomycin for Non-Muscle Invasive Bladder Cancer

The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is ...
Seeking Alpha

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...